Rui M. Gil da Costa

Dr. Rui M. Gil da Costa

Affiliation 1: Molecular Oncology and Viral Pathology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), 4200-072 Porto, Portugal
+1
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
MLMark P. Labrecque
Mark P. Labrecque
ICIlsa M. Coleman
Ilsa M. Coleman
LBLisha G. Brown
Lisha G. Brown
LTLawrence D. True
Lawrence D. True
LKLori Kollath
Lori Kollath
CMColm Morrissey
Colm Morrissey
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with diverse drivers of disease progression and mechanisms of therapeutic resistance. We conducted deep phenotypic characterization of CRPC metastases and patient-derived xenograft (PDX) lines using whole-genome RNA sequencing, gene set enrichment analysis, and immunohistochemistry. Our analyses revealed 5 mCRPC phenotypes based on the expression of well-characterized androgen receptor (AR) or neuroendocrine (NE) genes: AR-high tumors (ARPC), AR-low tumors (ARLPC), amphicrine tumors composed of cells coexpressing AR and NE genes (AMPC), double-negative tumors (i.e., AR–/NE–; DNPC), and tumors with small cell or NE gene expression without AR activity (SCNPC). RE1 silencing transcription factor (REST) activity, which suppresses NE gene expression, was lost in AMPC and SCNPC PDX models. However, knockdown of REST in cell lines revealed that attenuated REST activity drives the AMPC phenotype but is not sufficient for SCNPC conversion. We also identified a subtype of DNPC tumors with squamous differentiation and generated an encompassing 26-gene transcriptional signature that distinguished the 5 mCRPC phenotypes. Together, our data highlight the central role of AR and REST in classifying treatment-resistant mCRPC phenotypes. These molecular classifications could potentially guide future therapeutic studies and clinical trial design.

21 May 2013 in Lab Animal
Verified
Journal Article
Closed access
Ana I. Faustino-RochaAna I. Faustino-Rocha
Ana I. Faustino-Rocha
Paula A. OliveiraPaula A. Oliveira
Paula A. Oliveira
JPJacinta Pinho
Jacinta Pinho
CTCatarina Teixeira-Guedes
Catarina Teixeira-Guedes
RSRuben Soares-Maia
Ruben Soares-Maia
JCJorge Colaço
Jorge Colaço

6 March 2020 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
SSSara Peixoto da Silva
Sara Peixoto da Silva
Joana SantosJoana Santos
Joana Santos
MSMaria Paula Costa e Silva
Maria Paula Costa e Silva
Rui M. Gil da CostaRui M. Gil da Costa
Rui M. Gil da Costa
Rui MedeirosRui Medeiros
Rui Medeiros
Cancer cachexia is a multifactorial syndrome characterized by a progressive loss of skeletal muscle mass, along with adipose tissue wasting, systemic inflammation and other metabolic abnormalities leading to functional impairment. Cancer cachexia has long been recognized as a direct cause of complications in cancer patients, reducing quality of life and worsening disease outcomes. Some related conditions, like sarcopenia (age‐related muscle wasting), anorexia (appetite loss) and asthenia (reduced muscular strength and fatigue), share some key features with cancer cachexia, such as weakness and systemic inflammation. Understanding the interplay and the differences between these conditions is critical to advance basic and translational research in this field, improving the accuracy of diagnosis and contributing to finally achieve effective therapies for affected patients.

8 May 2012 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
RPRenata A.N. Pértile
Renata A.N. Pértile
SMSusana Margarida Gomes Moreira
Susana Margarida Gomes Moreira
Rui M. Gil da CostaRui M. Gil da Costa
Rui M. Gil da Costa
ACAlexandra Correia
Alexandra Correia
LGLuisa Guãrdao
Luisa Guãrdao
Miguel GamaMiguel Gama
Miguel Gama
The bacterial cellulose (BC) secreted by Gluconacetobacter xylinus is a network of pure cellulose nanofibres which has high crystallinity, wettability and mechanical strength. These characteristics...

1 February 2019 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
DEDiogo Estêvão
Diogo Estêvão
NCNatália Rios Costa
Natália Rios Costa
Rui M. Gil da CostaRui M. Gil da Costa
Rui M. Gil da Costa
Rui MedeirosRui Medeiros
Rui Medeiros

23 July 2013 in Critical Reviews in Toxicology
Verified
Journal Article
Closed access
MAM. Helena R. Amorim
M. Helena R. Amorim
Rui M. Gil da CostaRui M. Gil da Costa
Rui M. Gil da Costa
CLCarlos Lopes
Carlos Lopes
MBMargarida M. S. M. Bastos
Margarida M. S. M. Bastos
Sesquiterpene lactones (STLs) present a wide range of biological activities, mostly based on their alkylating capabilities, which underlie their therapeutic potential. These compounds are the active constituents of a variety of plants, frequently used as herbal remedies. STLs such as artemisinin and its derivatives are in use as first-line antimalarials while others, such as parthenolide, have recently reached cancer clinical trials. However, the toxicological profile of these compounds must be thoroughly characterized, since the same properties that make STL useful medicines can also cause severe toxicity. STL-containing plants have long been known to induce a contact dermatitis in exposed farm workers, and also to cause several toxic syndromes in farm animals. More recently, concerns are been raised regarding the genotoxic potential of these compounds and the embryotoxicity of artemisinins. A growing number of STLs are being reported to be mutagenic in different in vitro and in vivo assays. As yet no systematic studies have been published, but the genotoxicity of STLs seems to depend not so much on direct DNA alkylation as on oxidative DNA damage and other partially elucidated mechanisms. As the medicinal use of these compounds increases, further studies of their toxic potential are needed, especially those focusing on the structural determinants of genotoxicity and embryotoxicity.